The global wound care medtech/biomed market from 2H 2024 through today (early 2026) is a study in a unique paradox. While the sector’s turnover continues its steady climb—projected to exceed $20–30 billion this year, depending on the inclusion criteria for certain adjacent categories—the traditional engines of growth, namely large-scale M&A, joint ventures, material licensing deals, and strategic consolidations from the “Big 10” (and even Top 20) firms, appear to be in a state of uncharacteristic stasis.
To the casual observer, the “deal drought” of the past 18 months might look like a loss of momentum. However, a deeper look reveals a more complex reality. My research for this analysis involved a systematic audit of the Top 10, 25, and 50 global wound care players, ranging from multi-billion dollar giants like Coloplast, Convatec, Essity, Mölnlycke, Smith & Nephew, and Solventum, to the next tier of ~20 global firms, privately-held US distributors, and emerging “Shadow Market” innovators across APAC and MENA.
What I found is not a lack of activity, but a historic realignment of leadership, capital, and technology. While the Top 10–20 firms have been occupied with a costly “transition tax” of internal reorganizations and executive churn, a secondary tier of agile, cash-rich players is quietly reshuffling the deck. We are currently witnessing a pivot away from the “reimbursement arbitrage” of the early 2020s toward a “post-spread” market defined by clinical-operational merit, a shift in growth focus outside of North America and Western Europe, and the rise of AI-enabled diagnostics and tech-enabled, connected services.
The following 10 Strategic Drivers of the recent dealflow slowdown (at least for those not paying careful attention) represent the synthesis of this research. They provide a roadmap for executives, investors, analysts, and business-minded clinicians to navigate the institutional inertia of the giants while identifying the high-velocity “lifeboats” setting the pace for the next decade of wound management.
Driver 1: The CEO “Transition Tax” and the Institutional Inertia
The primary reason for the 2024–2025 deal drought is not a lack of capital, but a historic vacuum of leadership continuity at the top of the “Big 10.” M&A requires a clear strategic mandate, yet nearly every major player in the space has spent the last 18 months in a state of internal “house-cleaning.”
1. The “Efficiency Drive” at Smith & Nephew
Under the spotlight of activist investors like Elliott Investment Management, Smith & Nephew has been the market’s most volatile giant. The focus has shifted entirely to a radical “Efficiency Drive.” Throughout 2024 and 2025, we witnessed significant headcount reductions across the Advanced Wound Management (AWM) division. By tightening the integration of wound care into their sports medicine and orthopedics infrastructure, S&N has prioritized cost-containment over expansion. This friction has effectively turned a perennial “buyer” into a “seller,” evidenced by the Q1 2025 divestiture of Regranex to Lynch Regenerative Medicine.
2. Solventum: The $8 Billion “Startup” Legacy
The 3M spinoff in April 2024 created Solventum, a company that is essentially an $8.2 billion entity (with a massive ~$1.9B wound care footprint) operating with the soul of a startup and the baggage of a century-old giant. CEO Bryan Hanson has spent his first 18 months rebuilding an executive team and a Board where 50% of the members are new to the wound care legacy. This new leadership has been finding its operational footing—in Q1 2025 they announced the $4.1 billion sale of its Purification & Filtration business to Thermo Fisher, and in Q4 2025 they already announced their acquisition of Acera Surgical for $850 million ($725 million in upfront cash, plus $125 million in performance-based milestones) . Solventum had been sidelined from the large-scale medtech M&A they once dominated as they streamlined their strategy and portfolio, signaling that at this point, they are doubling down on the wound care and regenerative medicine aspect. It is still too early to know how their announced digital and related initiatives will play out. But the point is the “Transition Tax” led to a slow strategic buying activity period for them in the past 18 months, and in recent months we’re seeing new activity pick up as the new board, management team, and corporate identity/branding find their footing.
3. The Continuity Crisis: Convatec, Coloplast, Medline, and Integra
- Convatec: The tragic passing of CEO Karim Bitar in late 2025 has forced a period of internal stabilization. The appointment of former CFO Jonny Mason as CEO provides financial continuity, while David Shepherd’s transition to Chief Commercial Officer signals a shift toward commercial execution. Tanja Dormels has now stepped into the AWC leadership role (AWC COO) that Mr. Shepherd previously held to maintain the division’s momentum.
- Coloplast: Following the exit of Kristian Villumsen in May 2025, the return of Lars Rasmussen as Interim CEO signals a “Board-led reset” rather than an aggressive growth phase. The focus remains on integrating the Kerecis acquisition while the search for a permanent successor continues. However, significant strategic or corporate/investment moves have been difficult as a result.
- Medline: As it transitions into its post-IPO era, Medline is navigating its own generational leadership shift. With the announced retirement of President & COO Jim Pigott at the end of 2025, the elevation of Steve Miller (COO) and Amanda Laabs (Chief Product Officer) marks a pivot toward internal operational optimization over external brand acquisition. While mostly unknown in wound care outside of North America, they are actually a significant player in the US, with more market share than many of the multinational firms they compete with.
- Integra LifeSciences: No firm has been more “internally focused.” Between the hunt for a permanent successor to Jan De Witte (concluding with the appointment of Mojdeh Poul) and the massive remediation efforts surrounding the Boston facility recalls, Integra has effectively removed its checkbook from the market.
Diagnostic: The WCG Turbulence Index
| Segment | Status / Metric |
| Top 10 Global Firms | 70% had a change in CEO or Division President/EVP since Q3 2024. |
| Tier 2 (Ranks 11–25) | 55% underwent major restructuring or “efficiency layoffs.” |
| M&A Velocity | Down ~40% compared to the 2021–2023 peak period. |
Driver 2: The CTP Reimbursement Labyrinth
If leadership transitions provided the internal friction, the regulatory and reimbursement landscape for CTP (cellular and tissue products)—also known as CAMPs, “skin substitutes,” or “tissue”—provided the immediate existential risk. Between the cycle of withdrawn Local Coverage Determinations (LCDs) and the 2026 Physician Fee Schedule, the industry has been holding its breath.
1. From ASP to “Incident-To” Supplies
Effective January 1, 2026, CMS reclassified most skin substitutes from “biologic-like” products (ASP+6%) to “incident-to supplies.” By moving to a flat national rate—finalized at approximately $127 per square centimeter—CMS has effectively wiped out the “spread” that fueled the early 2020s.
2. The Strategic “Wait-and-See”
It is impossible to price an acquisition when the target’s primary revenue stream is under a regulatory guillotine. I am aware of at least one major global firm that walked away from a US CAMPs acquisition during due diligence because they couldn’t determine if they were buying a clinical asset or a short-term regulatory arbitrage play. While there is growth potential for this category outside the US, it is difficult to justify a major move without a compelling US case, which still represents 95%+ of global sales in this category.
3. “The Cops are at the Door”
As I told one investor in 2024: “Investing in high-spread tissue grafts right now is like getting to the party five minutes before the cops show up.” In 2026, the sirens are here. We are entering a “Post-Spread” market where products must survive on clinical merit and cost-efficiency.
Diagnostic: The CTP Viability Matrix
| Product Category | Regulatory Pathway | 2026 Status | Investor Sentiment |
| Section 351 Biologics | BLA (Full FDA) | Protected (ASP Based) | Moderate (Defensible but limited upside) |
| Section 361 HCT/Ps | Self-Designated | Flat Rate ($127/cm²) | Cautious (High Margin Risk) |
| 510(k) Devices | Medtech Clearance | Flat Rate ($127/cm²) | Stable (Volume Plays) |
Driver 3: The Cost of Capital Hangover
While leadership churn and reimbursement shifts provided the friction, the macro-environment provided the “external” paralysis. We are navigating the tail-end of a “Cost of Capital Hangover”—the adjustment period where the “Big 10” are sobering up from a decade of near-zero interest rates.
1. The Death of “Growth-at-all-Costs”
The surge in the risk-free rate has fundamentally repriced risk. In the 2010s, a 10% hurdle rate was a “green light” for strategic bets. In 2026, those hurdle rates have been recalibrated to 15–18%. For the “Big 10,” targets that once looked like “must-haves” at 6x revenue now fail the DCF test unless they possess a definitive “reimbursement moat” or are immediately EBITDA-positive.
2. The Bid-Ask Chasm & Structured Recovery
Founders remain anchored to 2021 “tourist pricing,” while corporate boards now demand “Profitable Efficiency.” To bridge this, over 50% of 2025 medical device deals utilized Earn-outs or Contingent Value Rights (CVRs) to shift risk back to the seller.
3. The Private Equity Bottleneck
The era of “easy exits” is over. Many PE sponsors who acquired wound care assets in the 2019–2021 window are now “over-tenured.” With the IPO window remaining selective, we are seeing a massive backlog of assets waiting for a “clearing event.”
The WCG Capital Pulse
| Metric | 2021 Peak | 2026 Current | Strategic Impact |
| Hurdle Rate | ~10% | 16%+ | De-prioritization of “long-shot” R&D. |
| Valuation | 8x–10x Rev | 4x–6x Rev | Only “Pure-Play” assets command premiums. |
| Structure | All-Cash | Structured | Heavy use of CVRs to mitigate valuation risk. |
Driver 4: The Digital Health Strategy Gap
Wound care has suffered from a “Digital Health Strategy Gap”—the chasm between AI-driven aspirations of startups and the “box-moving” reality of medtech giants.
1. The Google vs. Medtech Disconnect
Many startups born between 2015 and 2023 were premature or overvalued by VC expectations. They hit walls of regulatory friction and legacy EHR integration. With the exception of Tissue Analytics (acquired by Net Health in 2020), where I served on the Board of Directors, most struggled to find a repeatable model. A huge part of our unique value at Tissue Analytics was solving the EHR integration hurdle that continues to plague the sector.
2. 2024–2025: The Turning Point for “Connected Care”
2025 marked a pivot where giants began treating digital as a core commercial engine:
- Siren Care & Mölnlycke: Mölnlycke led a $9.5M round for Siren in early 2025. Backing a prevention-focused textile company is a radical departure for a traditional dressing manufacturer.
- FeelTect: Raised €1.5M in late 2025 for its pressure-sensing technology, focusing on pragmatic, clinical-first data generation in compression therapy.
- Corstrata: Beneficiary of the “CTP Labyrinth.” Providers are turning to Corstrata’s virtual care programs to survive the transition to value-based models.
Driver 5: Legislative Stagnation and the “Hospital-at-Home” Cliff
Persistent “Regulatory Purgatory” in Washington remains a barrier to scaling the next generation of care delivery.
1. The “Extension” Trap vs. Permanence
The industry is stuck in “can-kicking” mode. While Acute Hospital Care at Home (AHCaH) waivers provide temporary room, the lack of permanent legislation deters large-scale capital deployment from the “Big 10.”
2. Corstrata: The Strategic “Lifeboat”
As the CTP spread disappears, providers are incentivized to heal wounds cost-effectively. Corstrata has emerged as a critical “lifeboat” for provider groups navigating this shift. Historically, successful digital health in wound care requires a services layer—a “human-in-the-loop”—to drive adoption.
3. Shadow Alliances
Agile firms are forming “under-the-radar” alliances to pursue Value-Based Care (VBC) models. These will likely serve as the blueprint for the next wave of major service-medtech mergers once legislative permanence is achieved.
Diagnostic: WCG Policy & Services Pulse
| Legislative Trigger | Current Status (2026) | Strategic Requirement |
| Hospital-at-Home | Extension-based | Needs Legislative Permanence to catalyze ‘Big 10’ M&A. |
| Value-Based Care | Mandatory models expanding | Requires an Integrated Services Layer (e.g., Corstrata). |
| Digital Health | High churn / low fit | Success limited to firms with Clinical Service components. |
Driver 6: The Mid-Market “Stealth Reshuffle”
While the giants are paralyzed, mid-to-large privately held US distributors are undergoing a rapid reorganization.
1. The Agility Advantage
These firms, often fueled by cash built during the tissue boom and run by tightly knit management teams, are closing deals in weeks while global giants spend months in committee. I have witnessed this speed firsthand across multiple companies in the past year.
2. The Great Tissue Diversification
The end of the “reimbursement spread” is forcing evolution. While many pure-play distributors are downsizing, survivors are using cash reserves to diversify through licensing and equity stakes. The catalyst is the ‘CTP Labyrinth’ discussed in Driver #2.
3. Biolab Holdings: A Strategy with Global Ambitions
Biolab Holdings is playing offense with a mixture of US and international bets, shifting from simple distribution to deep scientific innovation and global tech integration. Their partnerships with German firms like cureVision and terraplasma medical, combined with heavy US human capital investment, make them a prime example of the new mid-market powerhouse. Along with Venture Medical, Royal Biologics, and Legacy Medical, these firms are using tissue-boom war chests to expand. I predict some of these agile players will oust several Top 20 global firms in the coming years.
Driver 7: The “Shadow Market” and the Global Center of Gravity Shift
A parallel universe of high-velocity deal flow is occurring in emerging markets, often without Western PR fanfare.
1. The “Launch-First” Strategy
The center of gravity in wound care is shifting East. In 2024 and 2025, I spent significantly more time visiting wound care providers and industrialists in Asia than in the US and Europe combined. Innovative technologies are increasingly choosing to launch in APAC, MENA, and LATAM regions first. These regions offer streamlined regulatory pathways and massive clinical need. Established firms are looking to grow their presence here too, especially given the global macro and tax/tariff uncertainties in legacy markets. While US reimbursement can drive billions in sales, the potential for cash pay and budgetary discretion in most non-US and non-Europe markets is an opportunity for many wound care companies to get organic revenue traction without the multi-year slog and especially high costs of regulatory and reimbursement processes.
2. Mölnlycke’s Emerging Dominance
Mölnlycke has proven to be one of the boldest of the “Big 5.” In May 2025, it expanded its stake in the Tamer Mölnlycke Care JV to 60%, establishing a hub for the Middle East. Simultaneously, it invested $135 million in its US (Maine) manufacturing facility and opened a dedicated site in China. These moves are a masterclass in navigating geopolitics and tariff-proofing while looking to the future.
Driver 8: The “Underwater Valuation Trap”
Much capital is paralyzed by the “valuation standoff.” Companies acquired post-2023 are often valued below their initial price, but sponsors hesitate to realize losses.
1. Fear of Realizing Losses
Corporate boards demand “profitable efficiency,” making them wary of recommending deals with lackluster growth histories—even if the technology is sound.
2. The Missing “Scaling Bridge”
Wound care lacks the defined “bridge” for scaling startups seen in cardiology or orthopedics. This keeps high-potential assets trapped on investor balance sheets waiting for a market correction that has yet to arrive.
Driver 9: The “Goldilocks” Target Scarcity
The “middle tier” of targets—companies with $50M to $500M in revenue—is essentially a desert in 2026.
1. The Revenue Mismatch
Giants want targets that can move the needle on quarterly earnings immediately. Most innovators are either too small (<$10M revenue) or too niche. From the acquirers’ perspective, many targets in this range would either cannibalize their existing business or bring on cost structures and liabilities that aren’t worth the acquisition price.
2. The Innovator’s Dilemma
Giants must either wait for targets to mature or get back into the business of building winners rather than just buying them.
Driver 10: The AI Integration Gap
The “Big 10” are struggling to translate AI hype into clinical and commercial reality. Very few even know how to evaluate digital health companies, much less AI-specific firms.
1. The Strategy Paradox
There is a fundamental gap between a Board’s desire for an “AI Strategy” and a C-Suite’s operational understanding of how to implement it without disrupting existing workflows.
2. The Regulatory and Privacy “Brake”
While AI models like Gemini provide revolutionary insights, the inability to safely ingest PHI prevents them from entering formal patient charts. State-level laws, like California’s 2026 requirements, have made enterprise-wide adoption a compliance minefield for slow-moving giants. If Driver 1 marks the leadership vacuum and Driver 2 identifies the regulatory labyrinth, Driver 10 highlights a fundamental identity crisis.
3. The Startup Collective
Startups are bypassing the giants to form “Shadow Ecosystems,” integrating AI-driven measurement and predictive analytics into unified platforms before the traditional players can even finalize a materials science pivot.
Conclusion: The Path Forward in a Realigned Market
The 2024–present “deal drought” was never a sign of industry decline, but a necessary period of structural realignment. Data across the Top 10, 25, and 50 global players indicates that institutional inertia is nearing its end. The industry that emerges will be defined by a greater global focus, new players with modern and refined portfolios, and integrated services that leverage the new wave of digital and AI-enabled medtech.
Via our holding, operating, and portfolio companies (which give me a priceless perspective into the industry from different angles), we have advised 80% of the top 20 global wound care brands, hundreds of institutional investors, and overseen numerous M&A and IPO events since 2018. My vantage point—spanning four continents—confirms that while the “Big 10” and even “Top 25” have been catching their breath, a significant number of important investment and partnership deals have occurred largely unnoticed.
The next wave of market leaders is already in motion. The “cops have shown up” to the old party, but for those focused on genuine clinical-commercial transformation, the real work is just beginning.